WASHINGTON (Azat TV) – The recent death of beloved actress Catherine O’Hara from a pulmonary embolism has brought renewed public attention to this critical medical condition, coinciding with growing concerns among researchers regarding its increased prevalence following COVID-19 infection. Studies are now highlighting a significant link between even mild cases of COVID-19 and an elevated risk of pulmonary embolism, prompting investigations into the long-term implications for public health.
Catherine O’Hara, 71, died on January 30, with her death certificate, released on February 9 by the Los Angeles County Medical Examiner’s Office, confirming pulmonary embolism as the cause. Rectal cancer was also listed as an underlying cause, according to reports from USA TODAY and ABC News. O’Hara, known for her prolific career including roles in the Apple series “The Studio” and the acclaimed “Schitt’s Creek,” reportedly experienced the onset of symptoms just hours before her passing.
Understanding Pulmonary Embolism and Its Severity
A pulmonary embolism (PE) occurs when a blood clot, most commonly originating from the deep veins in the legs (deep vein thrombosis or DVT), travels to the lungs and blocks an artery. This blockage severely impedes blood flow and oxygen levels, making it a medical emergency. The Cleveland Clinic reports that approximately 900,000 people in the United States experience a pulmonary embolism each year, with about 33% dying before receiving a diagnosis and treatment.
Symptoms of a pulmonary embolism can vary based on the clot’s size and any underlying health conditions, but common signs include sudden shortness of breath, chest pain, and fainting. Other indicators may include a cough, sometimes with bloody mucus, a rapid or irregular heartbeat, lightheadedness, excessive sweating, fever, leg pain or swelling, and clammy or discolored skin, as detailed by the Mayo Clinic.
COVID-19’s Lingering Impact: An Elevated PE Risk
Among the various risk factors for pulmonary embolism, medical conditions like heart disease, certain cancers, surgery, and clotting disorders have long been recognized. However, recent research underscores a particularly concerning link to COVID-19. Even individuals who experienced mild forms of the viral infection appear to face an increased risk of developing blood clots that can lead to a pulmonary embolism, a finding that has prompted a deeper look into the virus’s long-term effects on cardiovascular health.
This heightened risk post-COVID-19 suggests that the virus may induce lasting changes in the body’s clotting mechanisms, extending beyond the acute phase of infection. Researchers are actively investigating these mechanisms and the duration of this elevated risk, as the implications could affect millions worldwide who have contracted the virus. The ongoing studies aim to clarify how long this increased vulnerability persists and what preventative measures might be necessary for those with a history of COVID-19.
Risk Factors and Prevention Strategies for Pulmonary Embolism
Beyond the emerging link with COVID-19, several other factors can increase an individual’s susceptibility to pulmonary embolism. These include a personal or family history of blood clots, extended periods of inactivity such as long flights or bed rest, smoking, being overweight, supplemental estrogen use, and pregnancy. The Mayo Clinic emphasizes that while anyone can develop clots, awareness of these risk factors is crucial for prevention.
Preventative measures largely focus on reducing the likelihood of blood clot formation. Staying physically active, particularly during long periods of sitting, and using compression devices or leg elevation when advised by a medical professional can help. For individuals at high risk, healthcare providers may prescribe blood thinners. Timely diagnosis of a pulmonary embolism typically involves blood tests and imaging scans, with treatment options ranging from blood thinners to more aggressive therapies and procedures, depending on the severity of the condition.
The confluence of Catherine O’Hara’s death and the scientific community’s growing understanding of COVID-19’s cardiovascular aftermath underscores the urgent need for public awareness regarding pulmonary embolism. As studies continue to unravel the long-term health consequences of the pandemic, recognizing the signs and risk factors for this life-threatening condition, especially in the context of prior COVID-19 infection, becomes increasingly vital for early intervention and improved outcomes.